Company

Yun Ho Bio

Yun Ho Bio develops AI-assisted small nucleic acid drugs and RNAi therapies.

About

Founded in 2022 and based in Suzhou, China, Yun Ho Bio researches small nucleic acid drugs using AI-assisted RNAi approaches. Its platform combines drug development, multi-organ targeted delivery and chemical modification technologies. In March 2026, it closed a strategic investment round from Oriza Holdings.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in